This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Scott J. Stern, MD; Helmuth Goepfert, MD; Gary Clayman, MD, DDS; Robert Byers, MD; K. Kian Ang, MD; Adel K. El-Naggar, MD, PhD; Pat Wolf

Arch Otolaryngol Head Neck Surg. 1993;119(9):964-969.

Abstract
Eighty-five patients with squamous cell cancer of the maxillary sinus received all of their treatment at The University of Texas M. D. Anderson Cancer Center between the years 1971 and 1986. Their records were evaluated according to stage, disease at presentation, symptoms and signs at presentation, treatment, and outcome. There were no differences in locoregional control or survival between groups treated with surgery alone vs surgery plus radiotherapy. Careful analysis of the data indicates that there was almost certainly some selection bias for the patients undergoing combination therapy, as most of this group had historically adverse prognostic factors identified. Those patients who underwent radiotherapy alone or chemotherapy presented with either metastatic or locally advanced disease and were treated with palliative intent; therefore, comparison between this group and standard therapy groups was impossible in this retrospective review. Although it is tempting to speculate that combination therapy improved locoregional control and survival in patients with more advanced disease, none of the data presented in this review reach statistical significance. Furthermore, there is no difference in survival in this population compared with a study at this institution 20 years ago. Squamous cell cancer of the maxillary sinus continues to be a challenging neoplasm. Radiotherapy may improve locoregional control and survival in a group of patients with more advanced disease and may have its greatest utility in earlierstage disease. A multi-institutional prospective trial is needed to find ways to improve outcome in this patient population.

(Arch Otolaryngol Head Neck Surg. 1993;119:964-969)

Author Affiliations
From the Department of Otolaryngology—Head and Neck Surgery, The University of Arkansas for Medical Sciences, Little Rock (Dr Stern), and the Departments of Head and Neck Surgery (Drs Goepfert, Clayman, and Byers and Ms Wolf), Radiotherapy (Dr Ang), and Pathology (Dr El-Naggar), The University of Texas M. D. Anderson Cancer Center, Houston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Lymph Node Metastases in Malignant Tumors of the Paranasal Sinuses: Prognostic Value and Treatment
Cantu et al.
Arch Otolaryngol Head Neck Surg 2008;134:170-177.
ABSTRACT | FULL TEXT  

Survival and Staging Characteristics for Non-Squamous Cell Malignancies of the Maxillary Sinus
Bhattacharyya
Arch Otolaryngol Head Neck Surg 2003;129:334-337.
ABSTRACT | FULL TEXT